Key terms
About GBIO
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GBIO news
Apr 19
7:40am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 28
8:44am ET
Third Harmonic Bio appoints McDonough to board of directors
Mar 07
8:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Generation Bio (GBIO), PepGen Inc. (PEPG)
Mar 07
7:00am ET
Analysts’ Top Healthcare Picks: Generation Bio (GBIO), Curaleaf Holdings (CURLF)
Mar 07
12:15am ET
JMP Securities Keeps Their Hold Rating on Generation Bio (GBIO)
Mar 06
4:38pm ET
Generation Bio reports Q4 EPS (53c), consensus (45c)
Jan 22
3:10pm ET
Analysts Conflicted on These Healthcare Names: Generation Bio (GBIO), RegenXBio (RGNX) and Halozyme (HALO)
Jan 22
2:21pm ET
Analysts’ Top Healthcare Picks: Ardelyx (ARDX), Generation Bio (GBIO)
No recent press releases are available for GBIO
GBIO Financials
Key terms
Ad Feedback
GBIO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GBIO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
